Direct thrombin inhibitor argatroban reduces stroke damage in 2 different models

Stroke

Volumn 45, Issue 3, 2014, Pages 896-899

  Lyden, Patrick ^a   Pereira, Benedict ^a   Chen, Bo ^a   Zhao, Lifu ^a   Lamb, Jessica ^a   Lei, I Farn ^a   Rajput, Padmesh ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Animal; Models; Stroke; Thrombin; Treatment outcome

Indexed keywords

ARGATROBAN; AXXORA; THROMBIN; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; PIPECOLIC ACID DERIVATIVE;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; BRAIN ISCHEMIA; CONTROLLED STUDY; LEARNING DISORDER; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORPHOMETRICS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BRAIN; CEREBROVASCULAR ACCIDENT; DRUG ANTAGONISM; DRUG EFFECT; LEARNING CURVE; MAZE TEST; PATHOLOGY; PSYCHOLOGICAL ASPECT; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

MODELS, ANIMAL; STROKE; THROMBIN; TREATMENT OUTCOME;

ANIMALS; BRAIN; BRAIN ISCHEMIA; LEARNING CURVE; MALE; MAZE LEARNING; PIPECOLIC ACIDS; PLATELET AGGREGATION INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; STROKE; THROMBIN;

EID: 84899152978     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.004488     Document Type: Article

References (14)

1. Chen B, Friedman B, Whitney MA, Winkle JA, Lei IF, Olson ES, et al. Thrombin activity associated with neuronal damage during acute focal ischemia. J Neumsci. 2012;32:7622-7631.
2. Morris DC, Zhang L, Zhang ZG, Lu M, Berens KL, Brown PM, et al. Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke. 2001;32:2635-2640.
3. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1, 026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467-477.
4. Fisher M, Feuerstein G, Howells DW, Hum PD, Kent TA, Savitz SI, et al; STAIR Group. Update of the stroke therapy academic industry round- Table preclinical recommendations. Stroke. 2009;40:2244-2250.
5. Lapchak PA, Zhang JH, Noble-Haeusslein LJ. RIGOR Guidelines: escalating STAIR and STEPS for effective translational research. Transl Stroke Res. 2013;4:279-285.
6. Van Winkle JA, Chen B, Lei IF, Pereira B, Rajput PS, Lyden PD. Concurrent middle cerebral artery occlusion and intra- Arterial drug infusion via ipsilateral common carotid artery catheter in the rat. J Neurosci Methods. 2013;213:63-69.
7. Lyden PD, Lonzo LM, Nunez SY, Dockstader T, Mathieu-Costello O, Zivin JA. Effect of ischemic cerebral volume changes on behavior. Behav Brain Res. 1997;87:59-67.
8. Lyden P, Lonzo L, Nunez S. Combination chemotherapy extends the therapeutic window to 60 minutes after stroke. J Neurotrauma. 1995;12:223-230.
9. Morris RG, Garrud P, Rawlins JN, O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature. 1982;297:681-683.
10. Rapp JH, Pan XM, Neumann M, Hong M, Hollenbeck K, Liu J. Microemboli composed of cholesterol crystals disrupt the blood-brain barrier and reduce cognition. Stroke. 2008;39:2354-2361.
11. Harrison FE, Reiserer RS, Tomarken AJ, McDonald MP. Spatial and nonspatial escape strategies in the Barnes maze. Learn Mem. 2006;13:809-819.
12. Le DT, Shin C, Jackson-Friedman C, Lyden PD. Quantitative effects of nefiracetam on spatial learning of rats after cerebral embolism. J Stroke Cerebrovasc Dis. 2001;10:99-105.
13. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17:472-476.
14. Macleod MR, Fisher M, O'Collins V, Sena ES, Dimagl U, Bath PM, et al. Good laboratory practice: preventing introduction of bias at the bench. Stroke. 2009;40:e50-e52. Stroke